Abvc Biopharma (ABVC) Interest & Investment Income (2015 - 2026)
Abvc Biopharma's (ABVC) quarterly Interest & Investment Income came in at $3765.0 in Q1 2026, down 80.26% YoY from $19071.0 in Q1 2025, and down 95.39% on a QoQ basis from $81606.0 in Q4 2025.
Abvc Biopharma (ABVC) Interest & Investment Income (2015 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 12 years of Interest & Investment Income data on file, last reported at $3765.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 80.26% year-over-year to $3765.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $151797.0 (up 48.27% YoY) and the FY2025 annual result came in at $167103.0, up 91.29% from the prior year.
- Interest & Investment Income declined to $3765.0 in Q1 2026, from $81606.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $81606.0 in Q4 2025 to a low of $3765.0 in Q1 2026.
- A 5-year average of $37148.5 and a median of $40175.0 in 2022 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2024 — Interest & Investment Income slumped 92.32% — and 2025, when it surged 585.36%.
- Tracing ABVC's Interest & Investment Income over 5 years: stood at $60463.0 in 2022, then tumbled by 38.01% to $37483.0 in 2023, then sank by 68.23% to $11907.0 in 2024, then surged by 585.36% to $81606.0 in 2025, then sank by 95.39% to $3765.0 in 2026.
- The last three Interest & Investment Income figures came in at $3765.0 (Q1 2026), $81606.0 (Q4 2025), and $47287.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - | 683.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 683.00 |
| Mar 31, 2026 | 3,765.00 |
| Dec 31, 2025 | 81,606.00 |
| Sep 30, 2025 | 47,287.00 |
| Jun 30, 2025 | 19,139.00 |
| Mar 31, 2025 | 19,071.00 |
| Dec 31, 2024 | 11,907.00 |
| Sep 30, 2024 | 44,261.00 |
| Jun 30, 2024 | 27,141.00 |
| Mar 31, 2024 | 4,049.00 |
| Dec 31, 2023 | 37,483.00 |
| Sep 30, 2023 | 40,246.00 |
| Jun 30, 2023 | 55,041.00 |
| Mar 31, 2023 | 52,711.00 |
| Dec 31, 2022 | 60,463.00 |
| Sep 30, 2022 | 48,164.00 |
| Jun 30, 2022 | 39,015.00 |
| Mar 31, 2022 | 40,175.00 |
| Dec 31, 2021 | -29,388.00 |
| Sep 30, 2021 | 9,333.00 |